Not So Different: A Podcast from The Center for Biosimilars

Show notes To learn more about the FDA approval of Zymfentra, click here . To learn more about the results from the LIBERTY trials, click here . 

  Show notes Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle? Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe Denosumab Biosimilar Demonstrates Positive...

Show notes For more information on Global Biosimilars Week, click here . To read our article series in honor of Global Biosimilars Week, you can check out part 1 , part 2 , and part 3 here. To watch the webinar The Center for Biosimilars collaborated with IGBA for Global Biosimilars Week, click here .

FDA Approves First Subcutaneous Infliximab Product Abrilada Approved as Second Interchangeable Humira Biosimilar Eye on Pharma: New GI Data and Byooviz Interchangeability Propel Biosimilars Into the Future Biosimilars Check-In: BI Launches Unbranded Adalimumab; New Omalizumab Deal; CRL for Insulin Aspart Eye on Pharma: Another CRL for Alvotech; Cimerli’s Growing Market Share; BBCIC Awarded Grant S...

Show Notes House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics Part 2: FDA Workshop Shares Manufacturer Perspective on the Value of Clinical Efficacy Testing Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward Alvotech’s Stelara Biosimilar Approved in Ja...

To read more about Dr. Gregory's commentary piece, click here . To read more about Cardinal Health's 2023 Biosimilars Report, click here . To learn more about adalimumab biosimilars, click here . To learn more about the adalimumab biosimilars that have launched so far in the US: Click here for the launch of Amjevita Click here for the launches of Hyrimoz, Hadlima, Yusimry, and Cyltezo Click here f...

Show Notes FDA Approves First MS Biosimilar Stelara and Enbrel Chosen for IRA Price Negotiation Biocon Biosimilar Quarterly Sales Up 106% STADA Earnings Project Record Breaking Profits for 2023 Despite Global Increase in Amjevita Sales, US Sales Dropped 63% Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility Cardinal Health Exec: How Adalimumab Biosimilars Can Reshap...

Show notes To read CFB's analysis of the paper, click here . To view the full version of the paper, click here . To learn more about the Biosimilars Forum and its members, click here . To read the IQVIA report cited in the paper, click here . To read the IQVIA report cited in the paper, click here .

Show Notes First Round of Adalimumab Biosimilar Launches in July Celltrion Launches Yuflyma on the US Market US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending? Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready? Despite Steep Discounts, Humira Biosimilars Are Priced Mor...

Show notes To learn more about the adalimumab products that have launched in the US so far, click here , here , here , or here . Crohn's & Colitis Educational Resources: Biosimilars: What You Should Know   What is a Biosimilar Video  

Show notes Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare Alvotech, Advanz Pharma Ex...

Show Notes FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings  ...

To learn more about Tasmina's Asembia 2023 presentation, click here . Check out the full AmerisourceBergen Biosimilar pipeline report . To listen to Brian's past appearance on Not So Different, click here .

Show notes To read all the articles within the supplement, click here . To read the article references in this episode, click here .

Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low...

To learn more about biosimilars to treat RA, click here . To learn more about rheumatologists’ perceptions about RA biosimilars, click here . To learn more about incentives for prescribing biosimilars, click here . To learn more about infliximab biosimilar adoption, click here . To learn more about the influx of adalimumab biosimilars to the US market, click here . To learn more about ustekinumab...

Show notes Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy Policy Recommendations for Improving Biosimilar Uptake in Belgium Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies Dr Ivo Abraham Column: The 2022 WHO Biosimilar Guidelines—Loosening the Reins or Changing...

Show notes To listen to our podcast with Cheryl Vaughn, vice president of clinical services at McKesson, discussed how McKesson's Intrafusion service helps manage infusion sites and aids in the administration of complex biologic drugs, including biosimilars, click here .

Show notes Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-presc...

Show notes To learn more about Vizient’s Pharmacy Outlook Report, click here . To read Dr. Dolan’s paper “Opportunities and Challenges in Biosimilar Uptake in Oncology published in The American Journal of Managed Care ®, click here . To read Dr. Dolan’s paper “Evolving Practices in Managing Costly Immunotherapy” published in The American Journal of Managed Care®, click here .

Show notes US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita   Canada Approves High-Concentration Humira Biosimilar https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar   Celltrion Submits BLA for Infliximab Biobetter https://www.centerforbiosimilars.com/view/celltri...

Show notes: To check out part 1 of this interview series (written Q&A with Samsung Bioepis’ Kyung-Ah Kim), click here . Coming soon, part 3 will be a video interview about the initial market response to ophthalmology biosimilars and how industry leaders can work together to increase uptake. To learn more about the approval of Cimerli, click here . To learn more about ophthalmology biosimilars,...

Top 10 stories of the year: 10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar 9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA 8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023 7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology 6. Report: Biosimilar Competition in Europe 5. Part 1: Biosimilars to...

To read more about adalimumab biosimilars, click here . To read more about ophthalmology biosimilars, click here . To learn more about the Inflation Reduction Act’s impact on biosimilars, click here . To read more about the reauthorization of the Biosimilars User Fee Amendment, click here . To learn more about interchangeability, click here .

Show notes Rezvoglar Becomes Second Interchangeable Insulin Biosimilar Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed The European Union Gains Another Ranibizumab Biosimilar Alvotech Snags Australian Approval for Adalimumab Biosimilar Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Org...